A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Overview

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in pediatric participants aged 4 to <18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to <18 years) and Cohort 2 (age 4 to <12 years), with two parts; for each cohort. Part A will evaluate the drug levels of BMS-986165 to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose levels in pediatric participants with moderate to severe plaque psoriasis. The 5-year long-term extension (LTE) period will observe the long-term safety and tolerability of deucravacitinib in pediatric participants with psoriasis who have completed Parts A or B of the study.

Full Title of Study: “A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: April 15, 2024

Interventions

  • Drug: Deucravacitinib
    • Specified dose on specified days
  • Other: Placebo matching deucravacitinib
    • Specified dose on specified days

Arms, Groups and Cohorts

  • Experimental: Active treatment deucravacitinib standard dose
  • Experimental: Active treatment deucravacitinib half-standard dose
  • Placebo Comparator: Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Geometric mean observed average concentration at steady state (Cavg.ss) for deucravacitinib at Week 2
    • Time Frame: Week 2
    • Part A
  • Maximum observed plasma concentration at steady state (Cmax.ss) for deucravacitinib at Week 2
    • Time Frame: Week 2
    • Part A
  • Trough observed plasma concentration (Ctrough) for deucravacitinib at Week 2
    • Time Frame: Week 2
    • Part A
  • Proportion of subjects with at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 16
    • Time Frame: Week 16
    • Part B
  • Proportion of subjects with an static Physician’s Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16
    • Time Frame: Week 16
    • Part B
  • Incidence of Adverse Events (AEs)
    • Time Frame: Up to 316 weeks
    • Long-term extension (LTE) Period
  • Incidence of serious adverse events (SAEs)
    • Time Frame: Up to 316 weeks
    • LTE Period
  • Monitoring of growth: Body weight
    • Time Frame: Up to 316 weeks
    • LTE Period
  • Monitoring of growth: Height
    • Time Frame: Up to 316 weeks
    • LTE Period
  • Monitoring of growth: Tanner staging (sexual maturation)
    • Time Frame: Up to 316 weeks
    • LTE Period

Secondary Measures

  • Incidence of Adverse Events (AEs)
    • Time Frame: Up to 424 days
    • Part A and Part B
  • Incidence of serious adverse events (SAEs)
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Hematology tests
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Chemistry panel tests
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Hemoglobin A1C tests
    • Time Frame: Up to 410 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Infectious serologies tests
    • Time Frame: Up to 42 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Tuberculosis (TB) tests
    • Time Frame: Up to 42 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Lipid panel tests
    • Time Frame: Up to 368 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Serum immunoglobulin level tests
    • Time Frame: Up to 368 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Fasting plasma glucose tests
    • Time Frame: Up to 368 days
    • Part A and Part B
  • Incidence of clinically significant changes in clinical laboratory results: Pregnancy test for women of childbearing potential only
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in lymphocyte subsets and function
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in cytokine levels
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in physical examination findings
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in vital signs: Body temperature
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in vital signs: Respiratory rate
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in vital signs: Systolic and diastolic blood pressure
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Incidence of clinically significant changes in vital signs: Heart rate
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Monitoring of growth: Body weight
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Monitoring of growth: Height
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Monitoring of growth: Tanner staging (sexual maturation)
    • Time Frame: Up to 466 days
    • Part A and Part B
  • Proportion of subjects with at least 75% improvement in PASI (PASI 75) at Week 16 for the comparison of the half-standard dose of deucravacitinib vs placebo
    • Time Frame: Week 16
    • Part B
  • Proportion of subjects with an sPGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16 for the comparison of the half-standard dose of deucravacitinib vs placebo
    • Time Frame: Week 16
    • Part B
  • Proportion of subjects with at least 90% improvement in PASI (PASI 90) at Week 16 for the comparison of deucravacitinib vs placebo
    • Time Frame: Week 16
    • Part B
  • Change from baseline in PASI at Week 16 for comparison of deucravacitinib vs placebo
    • Time Frame: Week 16
    • Part B
  • Change from baseline in BSA involvement at Week 16 for comparison of deucravacitinib vs placebo
    • Time Frame: Week 16
    • Part B
  • Change from baseline in CDLQI score at Week 16 for comparison of deucravacitinib vs placebo
    • Time Frame: Week 16
    • Part B
  • Change from baseline in subject reported visual analog scale (VAS) for subject’s assessment of joint pain at Week 16 (only for subjects with confirmed JPsA prior to baseline) for comparison of deucravacitinib vs placebo
    • Time Frame: Week 16
    • Part B
  • Change from baseline in VAS for subject’s Global Assessment of Joint Disease; at Week 16 (only for subjects with confirmed JPsA prior to baseline) for comparison of deucravacitinib vs placebo
    • Time Frame: Week 16
    • Part B
  • Proportion of subjects achieving American College of Rheumatology Pediatric 30 (ACR Pedi 30) response at Week 16 for subjects with confirmed JPsA prior to baseline
    • Time Frame: Week 16
    • Part B ACR Pedi 30 response is defined as subjects with at least 30% improvement from baseline in 3 of any 6 variables in the core set, while no more than one of the remaining variables can worsen by > 30% for comparison of deucravacitinib vs placebo
  • Proportion of subjects using topical corticosteroid at Week 16 for comparison of deucravacitinib vs placebo
    • Time Frame: Week 16
    • Part B
  • Proportion of subjects with protective titers of antibodies to measles, tetanus and pertussis at Week 16
    • Time Frame: Week 16
    • Part B
  • Geometric mean observed average concentration at steady state (Cavg.ss) for deucravacitinib at Week 16
    • Time Frame: Week 16
    • Part B
  • Maximum observed plasma concentration at steady state (Cmax.ss) for deucravacitinib at Week 16
    • Time Frame: Week 16
    • Part B
  • Trough observed plasma concentration (Ctrough) for deucravacitinib at Week 16
    • Time Frame: Week 16
    • Part B
  • Proportion of participants with 75% improvement in PASI (PASI 75) over time
    • Time Frame: Up to 316 weeks
    • LTE Period
  • Proportion of participants with an sPGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline over time
    • Time Frame: Up to 316 weeks
    • LTE Period

Participating in This Clinical Trial

Inclusion Criteria

  • Males and females aged 12 to <18 years for Cohort 1. Males and females aged 4 to <12 years for Cohort 2. – Plaque psoriasis for at least 6 months – Moderate to severe disease – Candidate for phototherapy or systemic therapy – Must have completed the Week 52 treatment period in Part A or B for long-term extension (LTE) period Exclusion Criteria:

  • Participants weighing ≤ 30.0 kg at screening for Cohort 1 (age 12 to < 18 years), Part A and Part B. Participants weighing ≤ 18.0 kg at screening for Cohort 2 (age 4 to < 12 years), Part A and Part B. – Other forms of psoriasis – History of recent infection – Prior exposure to deucravacitinib (BMS-986165) or active comparator – Evidence of active TB for LTE period Other protocol-defined inclusion/exclusion criteria apply

Gender Eligibility: All

Minimum Age: 4 Years

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bristol-Myers Squibb
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bristol-Myers Squibb, Study Director, Bristol-Myers Squibb
  • Overall Contact(s)
    • BMS Study Connect Contact Center www.BMSStudyConnect.com, 855-907-3286, Clinical.Trials@bms.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.